|
INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016 open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15 |
Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter
Copyright Infringement Claims
Indexing Partner
|
Published Paper Details
|
|
| Paper Title: | A Comprehensive Review on Ivacaftor |
| Authors Name: | Radheshyam Sonar , Rutwik Talokar , Ved Yawalikar, , Aditya Ubhale |
| Unique Id: | IJSDR2212057 |
| Published In: | Volume 7 Issue 12, December-2022 |
| Abstract: | Cystic fibrosis (CF) is multisystemic disorder presenting in new born period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene. ∆F508 is the most common mutation seen worldwide. Supportive management with bronchodilators, anti-inflammatory, mucolytics, antibiotics are the corner stone of therapy. Mutation specific drug, Ivacaftor, was recently approved USFDA in January 2012 for patients carrying G551D mutation. It is approved in patients who are six years and older in 150 mg twice daily dosing schedule with fat containing meals. It improves the lung function and other aspects of disease including weight gain. The side effects like upper respiratory infection, headache, rash, diarrhoea, stomach ache and dizziness are mild and self-limiting. This is excellent example of promise of personalised medicine – targeted drug that treat patients with specific genetic makeup. Ivacaftor is First drug that treats an underlying cause of cystic fibrosis to be licensed for use Increases the open probability (i.e. gating) of cystic fibrosis transmembrane conductance regulator channels with the G551D mutation, thus augmenting chloride transport Convenient oral administration Improves lung function and bodyweight parameters when used in combination with standard care in adults, adolescents and children (aged C6 years) with cystic fibrosis and the G551D mutation Generally well tolerated. |
| Keywords: | Ivacaftor, cystic fibrosis, treatment of cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) potentiators, synthesis of ivacaftor |
| Cite Article: | "A Comprehensive Review on Ivacaftor", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.7, Issue 12, page no.383 - 392, December-2022, Available :http://www.ijsdr.org/papers/IJSDR2212057.pdf |
| Downloads: | 000337070 |
| Publication Details: | Published Paper ID: IJSDR2212057 Registration ID:202944 Published In: Volume 7 Issue 12, December-2022 DOI (Digital Object Identifier): Page No: 383 - 392 Publisher: IJSDR | www.ijsdr.org ISSN Number: 2455-2631 |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijsdr.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
Track Paper
Important Links
Conference Proposal
ISSN
 |
 |
DOI (A digital object identifier)
  Providing A digital object identifier by DOI How to GET DOI and Hard Copy Related |
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
 |
 |
 |
Social Media
Indexing Partner |
|||
| Copyright © 2024 - All Rights Reserved - IJSDR | |||
Facebook Twitter Instagram LinkedIn